First Own Gerresheimer Autoinjector - Gerresheimer & Midas Pharma Announce Strategic Partnership

Gerresheimer recently announced it has acquired the IP of a new generation cartridge-based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector. The go-to-market approach for the autoinjector combines the complementary strengths of both companies – Gerresheimer as a solution provider for medical devices and primary packaging solutions and Midas Pharma as experienced facilitator for global pharma projects and provider of products and services along the pharmaceutical value chain.

The new Gerresheimer autoinjector offers biotech and pharma companies as well as patients new opportunities in the treatment of various diseases. The new-generation autoinjector is suitable for subcutaneous injection with up to 3-ml injection volume. The patient-friendly, robust cartridge-based autoinjector will serve as a flexible and adaptable platform for a range of different products in a variety of therapeutic areas. These include highly viscous formulations of biological APIs like new biological entities and biosimilars. With this autoinjector development – based on own IP- Gerresheimer enhances its existing broad portfolio of medical devices such as various on-body injector solutions and wearable injector systems.

“The strategic partnership with Midas Pharma around this innovative autoinjector is an important milestone on our way to be a solution provider offering leading and innovative medical devices. With an increasing focus on own-IP products, we enhance our broad portfolio of devices and pharmaceutical primary packaging with this cartridge based autoinjector,” said Dietmar Siemssen, CEO of Gerresheimer AG. “We see this as a starting point for a successful cooperation with Midas Pharma and their expertise as pharma service provider.”

Karl-Heinz Schleicher, owner and CEO of Midas Pharma, added “The alliance with Gerresheimer is based on trust, a similar mindset and mutual goals. We consider the cooperation with Gerresheimer AG as a highly important strategic alliance, which we are fully committed to.”

The two companies will offer biotech and pharma customers a one-stop-shop around the autoinjector solution: Starting with the selection and delivery for the best solution of a medical device and associated primary packaging plus sourcing of the active pharmaceutical ingredients, through the entire development (technical, pharmaceutical and clinical) and registration. It also includes commercial manufacturing and supply of the ready filled, sterilized and assembled drug-device-combination, supported by a full range of complementary services, eg, quality, technical and analytical, regulatory, IP or project management.

Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence, focus on quality and customers. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people’s health and well-being.

Midas Pharma is a pharmaceutical company based in Ingelheim, Germany, that offers products, services and expertise along the entire pharmaceutical value chain – from Starting Materials and Active Pharmaceutical Ingredients to market ready Finished Products and Devices. Since over three decades the family-owned company has successfully contributed to the Pharma sector and has step by step expanded its competencies. For 2021 Midas Pharma Group is expecting an annual turnover of about 400 Mio. EUR. With more than 250 employees and 10 locations in all major pharmaceutical markets worldwide Midas Pharma has excellent local know-how, local contacts and well-established networks in different pharmaceutical sectors (biological products, small molecules and medical devices). Thanks to many years of experience and extensive expertise, Midas Pharma has a proven track record of successfully supporting its customers in coordinating even complex pharmaceutical projects and creating significant added value.